Recursion Pharmaceuticals (RXRX) Stock Overview
A clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RXRX Community Fair Values
Create NarrativeSee what 163 others think this stock is worth. Follow their fair value or set your own to get alerts.
Recursion Pharmaceuticals! WTH is going on?
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Recursion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.77 |
| 52 Week High | US$8.59 |
| 52 Week Low | US$2.98 |
| Beta | 0.95 |
| 1 Month Change | -18.04% |
| 3 Month Change | -18.57% |
| 1 Year Change | -50.85% |
| 3 Year Change | -52.93% |
| 5 Year Change | n/a |
| Change since IPO | -87.96% |
Recent News & Updates
Recent updates
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic
Feb 25Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 07
Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win
Apr 11Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts
Mar 27
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Mar 12This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Mar 02Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Feb 14Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Shareholder Returns
| RXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 0.7% | 0.9% |
| 1Y | -50.8% | 30.2% | 17.5% |
Return vs Industry: RXRX underperformed the US Biotechs industry which returned 30.2% over the past year.
Return vs Market: RXRX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| RXRX volatility | |
|---|---|
| RXRX Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RXRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RXRX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 800 | Najat Khan | www.recursion.com |
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
Recursion Pharmaceuticals, Inc. Fundamentals Summary
| RXRX fundamental statistics | |
|---|---|
| Market cap | US$1.99b |
| Earnings (TTM) | -US$644.76m |
| Revenue (TTM) | US$74.68m |
Is RXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXRX income statement (TTM) | |
|---|---|
| Revenue | US$74.68m |
| Cost of Revenue | US$70.95m |
| Gross Profit | US$3.73m |
| Other Expenses | US$648.49m |
| Earnings | -US$644.76m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 4.99% |
| Net Profit Margin | -863.35% |
| Debt/Equity Ratio | 1.6% |
How did RXRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/26 22:52 |
| End of Day Share Price | 2026/02/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gal Munda | Berenberg |
| Gaurav Goparaju | Berenberg |
| Alec Stranahan | BofA Global Research |